NCT07203092 Effects of Transcranial Photobiomodulation in ADHD
| NCT ID | NCT07203092 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Texas at Austin |
| Condition | Attention Deficit Hyperactivity Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 140 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2027-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 140 participants in total. It began in 2025-09-01 with a primary completion date of 2027-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators have previously shown that non-invasive methods of brain stimulation such as the administration of transcranial infrared light to the prefrontal cortex (PFC) can result in improvements to cognition and emotion as well as brain oxygenation. This method is called transcranial photobiomodulation (tPBM). The investigators hypothesize that tPBM can improve cognition and brain oxygenation in adults with attention deficit hyperactivity disorder (ADHD). The investigators will investigate the effects of repeated tPBM sessions on cognitive functioning in adults with ADHD. Specifically, the investigators hypothesize that participants that receive tPBM will show improvements in response control, sustained attention, and working memory, as well as improvements in prefrontal hemodynamics and a reduction in ADHD symptoms.
Eligibility Criteria
Inclusion Criteria: * English-speaking * Adults of any sex * Age range: 18-44 years * Any ethnic/racial background * Medical history of ADHD * Participants may either be on a stable ADHD medication regimen (with no changes within two weeks prior to the study) or not taking medication. Exclusion Criteria: * Currently pregnancy * Any sham or active photobiomodulation treatment within the past five weeks.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07203092 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 44 Years, studying Attention Deficit Hyperactivity Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07203092 currently recruiting?
Yes, NCT07203092 is actively recruiting participants. Contact the research team at UTBrainProject@gmail.com for enrollment information.
Where is the NCT07203092 trial being conducted?
This trial is being conducted at Austin, United States.
Who is sponsoring the NCT07203092 clinical trial?
NCT07203092 is sponsored by University of Texas at Austin. The trial plans to enroll 140 participants.